Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Repurchased
Growth Metrics
Income Statement
Others
Ratios

Ligand Pharmaceuticals (LGNDZ) Depreciation & Amortization (CF) (2016 - 2025)

Ligand Pharmaceuticals (LGNDZ) has disclosed Depreciation & Amortization (CF) for 16 consecutive years, with $8.2 million as the latest value for Q4 2025.

  • Quarterly Depreciation & Amortization (CF) fell 4.79% to $8.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $33.8 million through Dec 2025, down 4.15% year-over-year, with the annual reading at $33.8 million for FY2025, 4.15% down from the prior year.
  • Depreciation & Amortization (CF) hit $8.2 million in Q4 2025 for Ligand Pharmaceuticals, down from $8.3 million in the prior quarter.
  • In the past five years, Depreciation & Amortization (CF) ranged from a high of $13.7 million in Q1 2022 to a low of $8.2 million in Q4 2025.
  • Historically, Depreciation & Amortization (CF) has averaged $10.4 million across 5 years, with a median of $9.2 million in 2023.
  • Biggest five-year swings in Depreciation & Amortization (CF): soared 267.18% in 2021 and later tumbled 36.11% in 2023.
  • Year by year, Depreciation & Amortization (CF) stood at $13.2 million in 2021, then fell by 15.45% to $11.1 million in 2022, then fell by 19.93% to $8.9 million in 2023, then decreased by 3.24% to $8.6 million in 2024, then dropped by 4.79% to $8.2 million in 2025.
  • Business Quant data shows Depreciation & Amortization (CF) for LGNDZ at $8.2 million in Q4 2025, $8.3 million in Q3 2025, and $8.5 million in Q2 2025.